fumarates and Asthma

fumarates has been researched along with Asthma* in 4 studies

Reviews

1 review(s) available for fumarates and Asthma

ArticleYear
Anti-inflammatory dimethylfumarate: a potential new therapy for asthma?
    Mediators of inflammation, 2013, Volume: 2013

    Asthma is a chronic inflammatory disease of the airways, which results from the deregulated interaction of inflammatory cells and tissue forming cells. Beside the derangement of the epithelial cell layer, the most prominent tissue pathology of the asthmatic lung is the hypertrophy and hyperplasia of the airway smooth muscle cell (ASMC) bundles, which actively contributes to airway inflammation and remodeling. ASMCs of asthma patients secrete proinflammatory chemokines CXCL10, CCL11, and RANTES which attract immune cells into the airways and may thereby initiate inflammation. None of the available asthma drugs cures the disease--only symptoms are controlled. Dimethylfumarate (DMF) is used as an anti-inflammatory drug in psoriasis and showed promising results in phase III clinical studies in multiple sclerosis patients. In regard to asthma therapy, DMF has been anecdotally reported to reduce asthma symptoms in patients with psoriasis and asthma. Here we discuss the potential use of DMF as a novel therapy in asthma on the basis of in vitro studies of its inhibitory effect on ASMC proliferation and cytokine secretion in ASMCs.

    Topics: Anti-Inflammatory Agents; Asthma; Dimethyl Fumarate; Fumarates; Humans; Myocytes, Smooth Muscle

2013

Other Studies

3 other study(ies) available for fumarates and Asthma

ArticleYear
Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England.
    Respiratory medicine, 2022, Volume: 201

    A Markov cohort state transition model (focusing on exacerbations) was used to investigate the cost-effectiveness of medium- or high-dose BDP/FF/G vs medium- or high-dose BDP/FF, and high-dose BDP/FF/G vs high-dose BDP/FF + tiotropium. The model analysed cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER), and was developed from the England National Health Service perspective (2020 costs). Uncertainty of the inputs was estimated using one-way and probabilistic sensitivity analyses.. Both medium- and high-dose BDP/FF/G were cost-effective vs BDP/FF, with ICERs of £12,224 and £15,587 per QALY gained. High-dose BDP/FF/G was dominant vs BDP/FF + tiotropium, as it was both cheaper and gained QALYs. Sensitivity analyses were consistent with the base model: medium- and high-dose BDP/FF/G had 94.3% and 88.3% likelihoods to be cost-effective vs BDP/FF; high-dose BDP/FF/G had 100% likelihood to be a dominant strategy vs BDP/FF + tiotropium.. Both medium- and high-dose BDP/FF/G were cost-effective vs medium- and high-dose BDP/FF in adults with asthma that was uncontrolled by ICS/LABA. In addition, high-dose BDP/FF/G was a dominating strategy to high-dose BDP/FF + tiotropium.. GOV: NCT02676076 and NCT02676089.

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Asthma; Beclomethasone; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Formoterol Fumarate; Fumarates; Glycopyrrolate; Humans; Nebulizers and Vaporizers; State Medicine; Tiotropium Bromide

2022
Round table conference on tavegyl (HS 592).
    International archives of allergy and applied immunology, 1967, Volume: 31, Issue:6

    Topics: Asthma; Child; Child, Preschool; Fumarates; Histamine H1 Antagonists; Humans; Hypersensitivity; Rhinitis, Allergic, Seasonal; Skin Diseases

1967
[Utilization of new antihistaminic medication in the infant and child: HS 592].
    Lyon medical, 1967, Sep-03, Volume: 218, Issue:36

    Topics: Asthma; Fumarates; Histamine H1 Antagonists; Humans; Infant; Pyrrolidines; Respiratory Hypersensitivity

1967